The Global Rapid Microbiology Testing Market is projected to reach USD 6.7 billion by 2026 from USD 4.2 billion in 2021, at a CAGR of 9.4%.
Driver: Increasing incidence of infectious disease and cancer;
The incidence of various infectious diseases such as HIV, tuberculosis, malaria, and pneumonia has increased. With a rise in the global burden of these diseases, the demand for rapid microbiology techniques for faster and accurate microbial screening, identification, and susceptibility testing against pathogens is expected to witness significant growth during the forecast period
Opportunity: Growth opportunities in emerging countries;
Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the rapid microbiology testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infectious diseases, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries has drawn key players in the rapid microbiology testing market to focus on emerging countries.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31548521
“In 2020, instruments accounted for the largest share of the rapid microbiology testing market, by product”
The rapid microbiology testing market is segmented into instruments, reagents and kits and consumables based on product. The instrument segment accounted for the largest share of the rapid microbiology testing market in 2020, mainly due to the increased funding for R&D, increasing incidence of infectious disease and cancer and technological advancements.
“In 2020, growth-based rapid microbiology testing segment accounted for the largest share in the market, by method”
The rapid microbiology testing market is segmented into growth-based, cellular-based, nucleic acid-based, viability-based and other rapid microbiology testing based on method. In 2020, the growth-based rapid microbiology testing segment accounted for the largest share. Factors such as increased focus on the early detection of infectious disease increased funding for R&D and increased incidence of infectious disease and cancer.
“In 2020, clinical disease diagnosis segment accounted for the largest share in the market, by applications”The rapid microbiology testing market has been segmented into clinical disease diagnosis, food and beverage testing, pharmaceutican and biological drug testing, environmental testing, cosmetics and personal care products testing , research applications and other applications based on applications. In 2020, the clinical disease diagnostics segment accounted for the largest share of the rapid microbiology testing market. The increasing incidence of infectious disease and cancer is driving the growth of this segment.
Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=31548521
“North America is the largest regional market for rapid microbiology tests”
The global rapid microbiology testing market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global rapid microbiology testing market. The North American rapid microbiology testing market’s growth can be attributed to the, increased funding for R&D, increased focus on the early detection of infectious disease and increased incidence of infectious disease and cancer.
Some key players in the rapid microbiology testing market:
Abbott Laboratories, Inc. (US), Becton, Dickinson and Company (US), bioMérieux SA (France), Bruker Corporation (US), Charles River Laboratories International, Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), NEOGEN Corporation (US), Quidel Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (US), Don Whitley Scientific Limited (UK), Rapid Micro Biosystems, Inc. (US), Vivione Biosciences, LLC (US), Gradientech (Sweden), rqmicro AG (Switzerland), Bactest Ltd. (US), Colifast (Norway), Serosep Ltd. (Ireland), Biosensia (Ireland), Solus Scientific Solutions Ltd. (Scotland), LubioScience GmbH (Scotland), Euroclone SpA (OTCPK:ITALY), CorDx (US), and R-Biopharm AG (Germany).
